The Impower130 study showed that no survival benefit was observed in the EGFR-mutant subgroup administered atezolizumab and carboplatin/nab-paclitaxel (ACP regimen) compared to chemotherapy alone; however, the IMpower150 trial demonstrated that the addition of atezolizumab and bevacizumab to carboplatin/paclitaxel (ABCP regimen) significantly improved PFS and OS in EGFR-mutated NSCLC patients in contrast with bevacizumab plus carboplatin/paclitaxel (BCP regimen) [191–193]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.